| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Mar-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Sera Labs Operations | 6.1 | 1.0 | | | | | | |
| Cure Operations | 0.7 | 1.0 | 0.6 | | | | | |
| Total revenues [+] | 6.6 | 2.1 | 0.6 | 0.6 | 0.2 | 0.1 | 0.0 | 0.2 |
| Products | | | | 0.5 | 0.1 | 0.1 | 0.0 | 0.2 |
| Shipping & handling | | | | | | 0.0 | | 0.0 |
| Other income | | | | | 0.0 | 0.0 | | 0.0 |
| Revenue growth [+] | 219.6% | 229.2% | 6.7% | 223.7% | 114.3% | -54.1% | 0.0% | |
| Sera Labs Operations | 482.2% | | | | | | | |
| Cure Operations | -35.4% | 61.6% | | | | | | |
| Cost of goods sold | 2.2 | 1.1 | 0.2 | 0.3 | 0.2 | 0.2 | 0.0 | 0.1 |
| Gross profit | 4.4 | 1.0 | 0.4 | 0.3 | 0.0 | -0.1 | 0.0 | 0.1 |
| Gross margin | 66.8% | 47.5% | 62.9% | 52.1% | -0.1% | -82.2% | 88.7% | 36.2% |
| Selling, general and administrative [+] | 18.9 | 11.4 | 10.1 | 6.5 | 5.9 | 3.1 | 0.0 | 0.9 |
| General and administrative | | | | | | | 0.0 | |
| Research and development | 2.4 | 2.8 | 2.3 | 1.4 | 1.4 | 0.8 | | 0.7 |
| Equity in earnings | | | | 0.0 | | | | |
| Other operating expenses | 0.0 | | 1.6 | | | | | |
| EBITDA [+] | -13.3 | -12.3 | -13.0 | -7.4 | -7.2 | -3.8 | 0.0 | -1.4 |
| EBITDA growth | 8.5% | -5.9% | 76.3% | 3.0% | 91.2% | 172.4% | -12.5% | |
| EBITDA margin | -202.9% | -597.8% | -2092.1% | -1266.3% | -3978.6% | -4459.9% | -80.3% | -751.2% |
| Depreciation | 0.2 | 0.2 | 0.6 | 0.1 | 0.2 | 0.2 | 0.0 | 0.1 |
| EBITA | -13.5 | -12.5 | -13.6 | -7.5 | -7.3 | -3.9 | 0.0 | -1.5 |
| EBITA margin | -206.1% | -608.4% | -2184.8% | -1291.8% | -4069.8% | -4664.9% | -91.8% | -814.6% |
| Amortization of intangibles | 3.4 | 0.7 | | | | | | 0.0 |
| EBIT [+] | -16.9 | -13.2 | -13.6 | -7.5 | -7.3 | -3.9 | 0.0 | -1.5 |
| EBIT growth | 28.3% | -3.2% | 80.4% | 2.7% | 87.0% | 155.7% | 0.0% | |
| EBIT margin | -257.9% | -642.6% | -2184.8% | -1291.8% | -4069.8% | -4664.9% | -91.8% | -837.1% |
| Non-recurring items [+] | -1.8 | 5.8 | 0.1 | | | | | |
| Loss (gain) on sale of assets | 0.0 | | | | | | | |
| Unusual expense | -1.8 | 5.8 | 0.1 | | | | | |
| Interest expense, net [+] | 0.5 | 2.4 | 4.1 | 3.0 | 1.6 | 0.1 | | 0.2 |
| Interest expense | 0.6 | 2.5 | 4.1 | 3.0 | 1.6 | 0.1 | | 0.2 |
| Interest income | 0.1 | 0.0 | 0.1 | | 0.0 | 0.0 | | 0.0 |
| Other income (expense), net [+] | 2.4 | -9.2 | -3.6 | 0.2 | 0.8 | -0.1 | | 0.1 |
| Gain (loss) on debt retirement | 0.7 | | | | | | | |
| Other non-operating income | | | | | 0.0 | 0.0 | | 0.2 |
| Other non-ooperating expenses | | | | | 0.0 | -0.1 | | -0.1 |
| Other | 1.9 | -11.7 | 0.0 | -0.6 | -0.8 | -0.2 | | 0.0 |
| Pre-tax income | -13.2 | -30.6 | -21.4 | -10.4 | -8.2 | -4.2 | 0.0 | -1.6 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% |
| Minority interest | | | 0.0 | -10.4 | 0.0 | | | |
| Net income | -13.2 | -30.6 | -21.4 | -10.4 | -8.1 | -4.2 | 0.0 | -1.6 |
| Net margin | -201.3% | -1493.0% | -3430.7% | -1781.0% | -4517.6% | -4939.7% | -91.8% | -873.9% |
| |
| Basic EPS [+] | ($262.90) | ($647.27) | ($0.62) | ($0.42) | ($0.34) | ($0.46) | | ($0.24) |
| Growth | -59.4% | 104503.4% | 48.7% | 20.7% | -24.6% | 89.0% | | |
| Diluted EPS [+] | ($0.26) | ($0.65) | ($0.62) | ($0.42) | ($0.34) | ($0.46) | | ($0.24) |
| Growth | -59.4% | 4.6% | 48.7% | 20.7% | -24.6% | 89.0% | | |
| |
| Shares outstanding (basic) [+] | 0.1 | 0.0 | 34.5 | 25.0 | 23.6 | 9.1 | | 6.6 |
| Growth | 6.1% | -99.9% | 38.2% | 5.7% | 159.9% | 37.2% | | |
| Shares outstanding (diluted) [+] | 50.2 | 47.3 | 34.5 | 25.0 | 23.6 | 9.1 | | 6.6 |
| Growth | 6.1% | 37.0% | 38.2% | 5.7% | 159.9% | 37.2% | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |